01—Abstract
Summary
Summary of the 8-K filed May 2, 2024. Cited figures are marked; the original filing is the authoritative source.
BD (Becton, Dickinson and Company) reported fiscal Q2 2024 (quarter ended March 31, 2024) revenue of $5.045 billiona, up 4.6% as reported, 4.7% currency-neutral, and 5.7% organic.
GAAP diluted EPS rose 20.9% to $1.85b, and adjusted diluted EPS rose 10.8% to $3.17. Operating income grew 16.8% to $734 million. Growth was led by BD Interventional (up 9.0% reported, 13.6% organic, helped by Urology & Critical Care and Peripheral Intervention) and BD Medical (up 3.8%, driven by Medication Management Solutions and Medication Delivery Solutions).
BD Life Sciences grew 2.2%c, with Integrated Diagnostic Solutions offset by a decline in Biosciences. U.S. revenue rose 6.3%, while international revenue rose 2.4% as China market dynamics and currency pressured results. Cash generation improved meaningfully.
Year-to-date cash from continuing operations was $1.369 billiond, up $785 million, and free cash flow was $1.119 billion versus $195 million a year earlier. Management also repurchased $500 million of common stock year to date. Balance sheet leverage increased, with long-term debt rising to $15.995 billion from $14.738 billion at fiscal year-end 2023, while cash and short-term investments grew to about $3.2 billion.
The key guidance change is an increase in adjusted diluted EPS for fiscal 2024 to $12.95–$13.15 (from $12.82–$13.06), a midpoint increase of about 11 cents. Organic revenue growth guidance of 5.5%–6.25% was affirmed. Total revenue guidance was trimmed by about $100 million to roughly $20.1–$20.3 billion, reflecting a larger expected currency headwind (about 65 basis points to revenue growth, versus about 25 basis points previously).
The EPS raise was achieved despite an increased FX drag on EPS of about 425 basis points, up from about 360. Investors should note that GAAP EPS is heavily affected by purchase accounting amortization ($362 million pre-tax in the quarter) and restructuring charges ($98 million pre-tax), so the gap between GAAP and adjusted EPS remains large.
02—Key points
Key Highlights
- Q2 FY2024 revenue of $5.045B grew 4.6% reported and 5.7% organic, with BD Interventional up 13.6% organically, the strongest segment.
- GAAP diluted EPS rose 20.9% to $1.85, and adjusted diluted EPS rose 10.8% to $3.17; operating income grew 16.8% to $734M.
- Year-to-date free cash flow reached $1.119B versus $195M last year, and cash from continuing operations rose $785M to $1.369B.
- FY2024 adjusted EPS guidance was raised to $12.95–$13.15 (about +11 cents at midpoint), while organic revenue growth guidance of 5.5%–6.25% was affirmed.
- Total FY2024 revenue guidance was lowered by about $100M to roughly $20.1–$20.3B, driven by a larger FX headwind (about 65 bps versus 25 bps previously).
- Long-term debt increased to $15.995B from $14.738B, and BD repurchased $500M of common stock during the first half of the fiscal year.
- BD Alaris infusion system recovery progressed, with double-digit Infusion growth, though overall U.S. timing of the Alaris return to market remains a risk factor.
03—Questions
Frequently Asked Questions
Why did BD raise EPS guidance while lowering revenue guidance?
The revenue reduction of roughly $100M is mainly a currency effect. The estimated FX impact on revenue growth worsened to about (65) basis points from (25), while organic growth guidance was unchanged at 5.5%–6.25%. The EPS raise reflects operating performance and margin execution in the quarter, which management highlighted as the main driver, even though the FX drag on EPS increased to about (425) basis points from (360).
How do GAAP and adjusted EPS compare, and why is the gap so large?
Q2 GAAP diluted EPS was $1.85 versus adjusted EPS of $3.17. The largest adjustment is purchase accounting amortization, which totaled $362M pre-tax ($1.25 per share) in the quarter. Restructuring costs of $98M pre-tax ($0.34 per share) and European regulatory initiative costs of $24M pre-tax ($0.08 per share) also contributed. Management excludes these items to show underlying performance, but investors should weigh GAAP results alongside the adjustments, since they reflect real costs.
Which parts of the business are driving growth and which are lagging?
BD Interventional was the standout, up 13.6% organically, with Urology & Critical Care (licensing and PureWick growth) and Peripheral Intervention (Rotarex and Venclose) leading. BD Medical grew 3.8%, led by Medication Management Solutions (Alaris infusion progress) and Medication Delivery Solutions. BD Life Sciences grew 2.2%, supported by Integrated Diagnostic Solutions microbiology and Vacutainer, but Biosciences revenue fell as instrument sales declined and comparisons were tough against prior-year licensing revenue. China market dynamics were a drag in Medication Delivery Solutions and in international results more broadly.
How strong is BD's cash flow and capital position after the quarter?
Cash flow improved sharply: year-to-date free cash flow was $1.119B versus $195M, aided by lower working capital drag and lower capital expenditures ($250M versus $389M). BD also returned $500M through share repurchases and paid $550M in dividends. Debt rose, with long-term debt at $15.995B and current debt at $2.016B, as the company issued $1.972B of new long-term debt during the period. Cash and short-term investments reached about $3.2B, providing liquidity, but leverage is higher than at fiscal year-end 2023.
04—Continue